

Ronald F Van Vollenhoven

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/688412/ronald-f-van-vollenhoven-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

114
papers

13,918
citations

38
h-index

117
g-index

169
ext. papers

18,120
ext. citations

6.7
avg, IF

6.09
L-index

#	Paper	IF	Citations
114	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. <i>Arthritis Care and Research</i> , 2021 , 73, 1231-1235	4.7	10
113	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	4
112	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	7
111	Efficacy and Safety of Ustekinumab in Patients with Active Systemic Lupus Erythematosus: Results Through 2 Years of an Open-Label Extension in a Phase 2 Study. <i>Journal of Rheumatology</i> , 2021 ,	4.1	1
110	Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	1
109	Antirheumatic drugs for cardiovascular disease prevention: the case for colchicine. <i>RMD Open</i> , 2021 , 7,	5.9	1
108	What Does It Mean to Be a British Isles Lupus Assessment Group-Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials. <i>Arthritis and Rheumatology</i> , 2021 , 73, 2059-2068	9.5	2
107	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. <i>Lupus</i> , 2021 , 30, 1283-1288	2.6	2
106	Blood PD-1+TFh and CTLA-4+CD4+ T cells predict remission after CTLA-4Ig treatment in early rheumatoid arthritis. <i>Rheumatology</i> , 2021 ,	3.9	1
105	Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls. <i>Rheumatology</i> , 2021 , 60, 207-216	3.9	15
104	Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: a sub-analysis of the Phase 3 SELECT-EARLY study. <i>Modern Rheumatology</i> , 2021 , 31, 534-542	3.3	1
103	Mortality over 14 years in MTX-refractory patients randomized to a strategy of addition of infliximab or sulfasalazine and hydroxychloroquine. <i>Rheumatology</i> , 2021 , 60, 2217-2222	3.9	
102	Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies. <i>Lancet Rheumatology</i> , 2021 , 3, e778-e788	14.2	40
101	Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry" by Sparks. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	3
100	Achieving remission or low disease activity is associated with better outcomes in patients with systemic lupus erythematosus: a systematic literature review. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	2
99	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies.. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	5
98	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI). <i>Arthritis Care and Research</i> , 2020 ,	4.7	2

97	2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 713-723	2.4	173
96	Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1607-1620	9.5	56
95	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 685-699	3.4	851
94	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2020 , 72, 1800-1808	4.7	7
93	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. <i>Arthritis and Rheumatology</i> , 2020 , 72, 658-666	9.5	11
92	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2020 , 106, 102340	15.5	15
91	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 356-362	2.4	18
90	An updated matrix to predict rapid radiographic progression of early rheumatoid arthritis patients: pooled analyses from several databases. <i>Rheumatology</i> , 2020 , 59, 1842-1852	3.9	5
89	Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2020 , 72, 761-768	9.5	22
88	Patients with rheumatic diseases adhere to COVID-19 isolation measures more strictly than the general population. <i>Lancet Rheumatology, The</i> , 2020 , 2, e583-e585	14.2	23
87	Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib. <i>RMD Open</i> , 2020 , 6,	5.9	6
86	Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	40
85	Treat-to-target in rheumatoid arthritis - are we there yet?. <i>Nature Reviews Rheumatology</i> , 2019 , 15, 180-186	18.6	42
84	Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. <i>Journal of Rheumatology</i> , 2019 , 46, 492-500	4.1	7
83	Serum Biomarkers for Prediction of Response to Methotrexate Monotherapy in Early Rheumatoid Arthritis: Results from the SWEFOT Trial. <i>Journal of Rheumatology</i> , 2019 , 46, 555-563	4.1	8
82	Methotrexate for Prevention of Cardiovascular Events. <i>New England Journal of Medicine</i> , 2019 , 380, 2276-2272	9.9	2772
81	Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol. <i>BMJ Open</i> , 2019 , 9, e025687	3	49
80	Joint Mobilization of the Hands of Patients With Rheumatoid Arthritis: Results From an Assessor-Blinded, Randomized Crossover Trial. <i>Journal of Manipulative and Physiological Therapeutics</i> , 2019 , 42, 34-46	1.3	3

79	2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 736-745	2.4	628
78	A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 374-382	6.1	20
77	Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort. <i>Arthritis Care and Research</i> , 2019 , 71, 893-902	4.7	46
76	Definitions of remission in systemic lupus erythematosus: a post-hoc analysis of two randomised clinical trials. <i>Lancet Rheumatology, The</i> , 2019 , 1, e163-e173	14.2	9
75	Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies. <i>Expert Opinion on Biological Therapy</i> , 2019 , 19, 157-168	5.4	14
74	The relationship between remission and health-related quality of life in a cohort of SLE patients. <i>Rheumatology</i> , 2019 , 58, 628-635	3.9	18
73	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis Care and Research</i> , 2018 , 70, 1478-1487	4.7	36
72	A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 103, 1074-1082	6.1	24
71	Long-Term Dietary Changes after Diagnosis of Rheumatoid Arthritis in Swedish Women: Data from a Population-Based Cohort. <i>International Journal of Rheumatology</i> , 2018 , 2018, 9152480	2	3
70	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2018 , 70, 1294-1302	4.7	13
69	Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC study. <i>Lupus Science and Medicine</i> , 2018 , 5, e000288	4.6	6
68	Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort. <i>Lupus Science and Medicine</i> , 2018 , 5, e000287	4.6	7
67	Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. <i>Lancet, The</i> , 2018 , 392, 1330-1339	4.0	161
66	Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients. <i>Pharmacogenomics Journal</i> , 2018 , 18, 528-538	3.5	25
65	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 554-561	2.4	175
64	Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration. <i>Journal of Rheumatology</i> , 2017 , 44, 162-169	4.1	13
63	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 960-977	7.4	1649
62	Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor-methotrexate combination therapy versus triple therapy in rheumatoid arthritis. <i>RMD Open</i> , 2017 , 3, e000371	5.9	19

61	Disease activity patterns over time in patients with SLE: analysis of the Hopkins Lupus Cohort. <i>Lupus Science and Medicine</i> , 2017 , 4, e000192	4.6	34
60	Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1751-1761	9.5	55
59	Are dietary vitamin D, omega-3 fatty acids and folate associated with treatment results in patients with early rheumatoid arthritis? Data from a Swedish population-based prospective study. <i>BMJ Open</i> , 2017 , 7, e016154	3	11
58	A Multi-Biomarker Disease Activity Score and the Choice of Second-Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure. <i>Arthritis and Rheumatology</i> , 2017 , 69, 953-963	9.5	22
57	Fully automated joint space width measurement and digital X-ray radiogrammetry in early RA. <i>RMD Open</i> , 2017 , 3, e000369	5.9	6
56	Obesity is a strong predictor of worse clinical outcomes and treatment responses in early rheumatoid arthritis: results from the SWEFOT trial. <i>RMD Open</i> , 2017 , 3, e000458	5.9	34
55	Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. <i>Arthritis Research and Therapy</i> , 2017 , 19, 287	5.7	1
54	Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials. <i>Rheumatology</i> , 2017 , 56, 541-549	3.9	28
53	The frequency and outcome of lupus nephritis: results from an international inception cohort study. <i>Rheumatology</i> , 2016 , 55, 252-62	3.9	210
52	Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 52-8	2.4	88
51	Systemic lupus erythematosus. <i>Nature Reviews Disease Primers</i> , 2016 , 2, 16039	51.1	422
50	The association between diet and glucocorticoid treatment in patients with SLE. <i>Lupus Science and Medicine</i> , 2016 , 3, e000135	4.6	5
49	Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. <i>Arthritis Research and Therapy</i> , 2016 , 18, 50	5.7	27
48	Does disease activity at start of biologic therapy influence work-loss in RA patients?. <i>Rheumatology</i> , 2016 , 55, 729-34	3.9	5
47	Choosing Wisely in Daily Practice: An Intervention Study on Antinuclear Antibody Testing by Rheumatologists. <i>Arthritis Care and Research</i> , 2016 , 68, 562-9	4.7	11
46	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 16-22	2.4	156
45	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 3-15	2.4	814
44	Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials. <i>RMD Open</i> , 2016 , 2, e000323	5.9	11

43	Off-label use of rituximab for systemic lupus erythematosus in Europe. <i>Lupus Science and Medicine</i> , 2016 , 3, e000163	4.6	34
42	Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1081-91	2.4	119
41	Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab. <i>RMD Open</i> , 2016 , 2, e000213	2.1	30
40	Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trial. <i>RMD Open</i> , 2016 , 2, e000197	5.9	19
39	Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis. <i>RMD Open</i> , 2016 , 2, e000262	5.9	15
38	New therapeutic approaches in rheumatoid arthritis. <i>Presse Medicale</i> , 2016 , 45, e179-92	2.2	4
37	Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis. <i>Rheumatology</i> , 2016 , 55, 1031-41	3.9	46
36	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis. <i>Arthritis and Rheumatology</i> , 2016 , 68, 2174-83	9.5	75
35	Early treatment intensification induces favourable radiographic outcomes according to predicted versus observed radiographic progression in early rheumatoid arthritis: a subanalysis of the randomised FIN-RACo and NEO-RACo trials. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34, 1065-1071	2.2	5
34	Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1102-9	2.4	76
33	Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1567-70	2.4	25
32	Does disease activity at the start of biologic therapy influence health care costs in patients with RA?. <i>Rheumatology</i> , 2015 , 54, 1472-7	3.9	1
31	Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years. <i>Journal of Rheumatology</i> , 2015 , 42, 1761-6	4.1	142
30	Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1094-101	2.4	35
29	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1706-13	2.4	250
28	Brief report: enhancement of patient recruitment in rheumatoid arthritis clinical trials using a multi-biomarker disease activity score as an inclusion criterion. <i>Arthritis and Rheumatology</i> , 2015 , 67, 2855-60	9.5	7
27	Detection of clinically manifest and silent synovitis in the hands and wrists by fluorescence optical imaging. <i>RMD Open</i> , 2015 , 1, e000106	5.9	15
26	Serum survivin predicts responses to treatment in active rheumatoid arthritis: a post hoc analysis from the SWEFOT trial. <i>BMC Medicine</i> , 2015 , 13, 247	11.4	19

25	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 958-67	2.4	388
24	Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. <i>Lancet, The</i> , 2014 , 383, 321-32	4.0	196
23	94. Tocilizumab in Patients with Rheumatoid Arthritis and Rates of Malignancy: Results from Long-Term Extension Clinical Trials. <i>Rheumatology</i> , 2014 , 53, i91-i92	3.9	3
22	Response to CBDA: what is it good for? By Yazici et al. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, e73	2.4	4
21	Advances in the treatment of rheumatoid arthritis. <i>F1000prime Reports</i> , 2014 , 6, 31		36
20	Long-term follow-up in lupus nephritis patients treated with rituximab--clinical and histopathological response. <i>Rheumatology</i> , 2013 , 52, 847-55	3.9	39
19	Rheumatoid arthritis in 2012: Progress in RA genetics, pathology and therapy. <i>Nature Reviews Rheumatology</i> , 2013 , 9, 70-2	8.1	22
18	Oral Abstracts 7: RA Clinical * O37. Long-Term Outcomes of Early RA Patients Initiated with Adalimumab Plus Methotrexate Compared with Methotrexate Alone Following a Targeted Treatment Approach. <i>Rheumatology</i> , 2013 , 52, i44-i55	3.9	2
17	Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. <i>New England Journal of Medicine</i> , 2012 , 367, 508-19	59.2	658
16	Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1771-82	2.4	692
15	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012 , 64, 2677-86		2688
14	Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 469-75	2.4	128
13	A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2011 , 63, 3918-30		944
12	Unresolved issues in biologic therapy for rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2011 , 7, 205-15	8.1	27
11	Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. <i>Journal of Rheumatology</i> , 2010 , 37, 558-67	4.1	212
10	Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study. <i>Arthritis Care and Research</i> , 2010 , 62, 226-34	4.7	47
9	New and future agents in the treatment of rheumatoid arthritis. <i>Discovery Medicine</i> , 2010 , 9, 319-27	2.5	9
8	Sex differences in rheumatoid arthritis: more than meets the eye. <i>BMC Medicine</i> , 2009 , 7, 12	11.4	146

- 7 Treatment of rheumatoid arthritis: state of the art 2009. *Nature Reviews Rheumatology*, **2009**, 5, 531-41 8.1 170
- 6 Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. *Arthritis and Rheumatism*, **2007**, 56, 1263-72 175
- 5 Infliximab in the treatment of rheumatoid arthritis. *Aging Health*, **2006**, 2, 19-33 1
- 4 B cell lymphoproliferative disorders and VH4-34 gene encoded antibodies. *Human Antibodies*, **2004**, 13, 63-68 1.3 14
- 3 Clinical responses to tumor necrosis factor alpha antagonists do not show a bimodal distribution: data from the Stockholm tumor necrosis factor alpha followup registry. *Arthritis and Rheumatism*, **2003**, 48, 1500-3 43
- 2 Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious. *Arthritis Research*, **2003**, 5, R347-51 32
- 1 Dehydroepiandrosterone for the treatment of systemic lupus erythematosus. *Expert Opinion on Pharmacotherapy*, **2002**, 3, 23-31 4 34